↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Medori R) "

Search: WFRF:(Medori R)

Result 1-3 of 3

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Charvin, D, et al. (author) A Novel mglur4 compound alleviates motor symptoms in primate models of parkinson's disease 2017 In: JOURNAL OF THE NEUROLOGICAL SCIENCES. - : Elsevier BV. - 0022-510X. ; 381, s. 97-97 Conference paper (other academic/artistic)
2.	Charvin, D, et al. (author) An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates 2018 In: Movement disorders : official journal of the Movement Disorder Society. - : Wiley. - 1531-8257. ; 33:10, s. 1619-1631 Journal article (peer-reviewed)
3.	Hupperts, Raymond, et al. (author) Prolonged-release fampridine and walking and balance in MS: Randomised controlled MOBILE trial 2016 In: Multiple Sclerosis. - : SAGE Publications. - 1352-4585 .- 1477-0970. ; 22, s. 212-221 Journal article (peer-reviewed)abstract © SAGE Publications.Background: Mobility impairment is a common disability in MS and negatively impacts patients' lives. Objective: Evaluate the effect of prolonged-release (PR) fampridine (extended-release dalfampridine in the United States) on self-assessed walking disability, dynamic/static balance and safety in patients with MS. Methods: MOBILE was a randomised, double-blind, exploratory, placebo-controlled trial. Patients with progressive/relapsing-remitting MS and Expanded Disability Status Scale score of 4.0-7.0 were treated with PR-fampridine or placebo twice daily for 24 weeks. Efficacy endpoints included change from baseline in the 12-item MS Walking Scale (MSWS-12), Timed Up and Go (TUG) test and Berg Balance Scale (BBS). Results: 132 patients were randomised at 24 sites in six countries. PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks. A higher proportion of patients receiving PR-fampridine versus placebo experienced significant improvements at MSWS-12 improvement thresholds ≥7 (p = 0.0275), ≥8 (p = 0.0153) and ≥9 points (p = 0.0088) and TUG speed thresholds ≥10% (p = 0.0021) and ≥15% (p = 0.0262). PR-fampridine was well tolerated. Conclusions: PR-fampridine therapy resulted in early and sustained improvements in broad measures of walking and balance over six months.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-3 of 3

Refine your search

Type of publication: journal article (2); conference paper (1)

Type of content: peer-reviewed (2); other academic/artistic (1)

Author/Editor: Halldin, C (2); Takano, A (2); Bezard, E (2); Charvin, D (2); Di Paolo, T (2); Duvey, G (2); show more...; Gregoire, L (2); Pioli, E (2); Medori, R (2); Conquet, F (2); Lycke, Jan, 1956 (1); Hupperts, Raymond (1); Short, Christine (1); Gasperini, Claudio (1); McNeill, Manjit (1); Medori, Rossella (1); Tofil-Kaluza, Agata (1); Hovenden, Maria (1); Mehta, Lahar R. (1); Elkins, Jacob (1); show less...

University: Karolinska Institutet (2); University of Gothenburg (1)

Language: English (3)

Research subject (UKÄ/SCB): Medical and Health Sciences (2)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view